Analysts See $-0.12 EPS for Codexis, Inc. (CDXS); Assembly Biosciences (ASMB) SI Increased By 12.23%

April 26, 2018 - By Nellie Frank

Codexis, Inc. (NASDAQ:CDXS) Logo

Assembly Biosciences Inc (NASDAQ:ASMB) had an increase of 12.23% in short interest. ASMB’s SI was 399,200 shares in April as released by FINRA. Its up 12.23% from 355,700 shares previously. With 236,500 avg volume, 2 days are for Assembly Biosciences Inc (NASDAQ:ASMB)’s short sellers to cover ASMB’s short positions. The SI to Assembly Biosciences Inc’s float is 3.16%. The stock increased 1.03% or $0.45 during the last trading session, reaching $44.16. About 26,740 shares traded. Assembly Biosciences, Inc. (NASDAQ:ASMB) has risen 110.93% since April 26, 2017 and is uptrending. It has outperformed by 99.38% the S&P500.

Analysts expect Codexis, Inc. (NASDAQ:CDXS) to report $-0.12 EPS on May, 8.They anticipate $0.06 EPS change or 33.33% from last quarter’s $-0.18 EPS. After having $0.02 EPS previously, Codexis, Inc.’s analysts see -700.00% EPS growth. The stock increased 0.89% or $0.1 during the last trading session, reaching $11.3. About 88,995 shares traded. Codexis, Inc. (NASDAQ:CDXS) has risen 125.77% since April 26, 2017 and is uptrending. It has outperformed by 114.22% the S&P500.

Assembly Biosciences, Inc., a clinical stage biotechnology company, develops oral therapeutics for the treatment of hepatitis B virus infection and novel class of oral synthetic live biotherapeutics to restore health to a dysbiotic microbiome in the United States. The company has market cap of $902.16 million. It is involved in developing core protein allosteric modulators that modulate the HBV core protein at various points in the viral lifecycle. It currently has negative earnings. The firm also develops microbiome program, a platform that includes the identification and selection process to strain isolation and growth under current good manufacturing practice conditions; and a patent pending delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract.

Among 5 analysts covering Assembly Biosciences (NASDAQ:ASMB), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Assembly Biosciences had 6 analyst reports since November 8, 2017 according to SRatingsIntel. The stock of Assembly Biosciences, Inc. (NASDAQ:ASMB) has “Neutral” rating given on Friday, April 13 by Chardan Capital Markets. The stock has “Hold” rating by FBR Capital on Friday, March 9.

Among 4 analysts covering Codexis (NASDAQ:CDXS), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Codexis had 9 analyst reports since August 12, 2015 according to SRatingsIntel. As per Friday, October 13, the company rating was maintained by Jefferies. As per Monday, March 12, the company rating was maintained by H.C. Wainwright. The firm earned “Hold” rating on Wednesday, August 26 by Zacks. The company was downgraded on Thursday, January 26 by First Analysis. The firm has “Hold” rating given on Wednesday, August 12 by Zacks. The stock has “Buy” rating by Ladenburg Thalmann on Wednesday, January 4. The stock of Codexis, Inc. (NASDAQ:CDXS) has “Buy” rating given on Wednesday, January 6 by H.C. Wainwright.

Since March 21, 2018, it had 0 insider purchases, and 5 selling transactions for $1.19 million activity. NICOLS JOHN J also sold $259,828 worth of Codexis, Inc. (NASDAQ:CDXS) shares. On Wednesday, March 21 KELLEY BERNARD J sold $124,683 worth of Codexis, Inc. (NASDAQ:CDXS) or 10,206 shares. 6,000 shares were sold by Smith David V, worth $62,213 on Tuesday, April 3. WOLF DENNIS P sold 41,666 shares worth $464,384. Another trade for 25,000 shares valued at $276,318 was made by BARUCH THOMAS R on Wednesday, March 28.

Investors sentiment decreased to 2.17 in 2017 Q4. Its down 0.03, from 2.2 in 2017Q3. It is negative, as 3 investors sold Codexis, Inc. shares while 15 reduced holdings. 12 funds opened positions while 27 raised stakes. 28.02 million shares or 9.42% more from 25.60 million shares in 2017Q3 were reported. State Street reported 645,477 shares. Moreover, Burney Company has 0.01% invested in Codexis, Inc. (NASDAQ:CDXS) for 20,000 shares. Credit Suisse Ag reported 11,766 shares or 0% of all its holdings. White Pine Capital Ltd Liability, a Minnesota-based fund reported 56,040 shares. Bankshares Of Ny Mellon reported 161,350 shares or 0% of all its holdings. Envestnet Asset has invested 0% in Codexis, Inc. (NASDAQ:CDXS). Virtu Ltd Limited Liability Company invested in 24,209 shares. Moreover, Bridgeway Mgmt has 0% invested in Codexis, Inc. (NASDAQ:CDXS) for 14,500 shares. Stifel Corp owns 10,000 shares or 0% of their US portfolio. 64,489 are owned by California State Teachers Retirement Sys. Renaissance Technology Limited Liability Company reported 0% stake. Guggenheim Cap Ltd Liability Corporation holds 10,184 shares or 0% of its portfolio. Opaleye Inc reported 1.70M shares stake. State Board Of Administration Of Florida Retirement Systems invested 0% in Codexis, Inc. (NASDAQ:CDXS). Ameriprise Financial invested in 0% or 95,500 shares.

Codexis, Inc. (NASDAQ:CDXS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: